Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Redcare Pharmacy NVSHPPF 69 Debt-to-EBITDA is 6.16 as of Mar. 2026. GuruFocus rates SHPPF with a GF Score™ of 69/100 and a GF Value™ of $175.28 (Significantly Undervalued). The stock has 2 warning signs investors should review. Among 477 Healthcare Providers & Services companies, Redcare Pharmacy NV ranks worse than 85.74% on this metric.
Debt-to-EBITDA measures a company's ability to pay off its debt.
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
The historical rank and industry rank for Redcare Pharmacy NV's Debt-to-EBITDA or its related term are showing as below:
SHPPF'
s Debt-to-EBITDA Range Over the Past 10 Years
Min: -7.52 Med: -0.51 Max: 8.77
Current: 7.58
During the past 13 years, the highest Debt-to-EBITDA Ratio of Redcare Pharmacy NV was 8.77. The lowest was -7.52. And the median was -0.51.
SHPPF's Debt-to-EBITDA is ranked worse than 85.74% of 477
companies
in the Healthcare Providers & Services industry
Industry Median: 2.22
vs SHPPF: 7.58
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.
According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
Redcare Pharmacy NV Debt-to-EBITDA Related Terms
Redcare Pharmacy NV Debt-to-EBITDA Historical Data
* Premium members only.
The historical data trend for Redcare Pharmacy NV's Debt-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Pharmaceutical Retailers subindustry, Redcare Pharmacy NV's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Redcare Pharmacy NV Debt-to-EBITDA vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Redcare Pharmacy NV's Debt-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Redcare Pharmacy NV's Debt-to-EBITDA falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data,
the EBITDA data used here is four times the quarterly (Mar. 2026) EBITDA data.
Redcare Pharmacy NV (SHPPF) has a Debt-to-EBITDA of 6.16 as of Mar. 2026. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Redcare Pharmacy NV. According to the industry distribution chart, Redcare Pharmacy NV ranks #409 out of 477 companies in the Healthcare Providers & Services industry, placing it in the top 85.7%.
Is Redcare Pharmacy NV's Debt-to-EBITDA too high?
Redcare Pharmacy NV's current Debt-to-EBITDA is 6.16. The Healthcare Providers & Services industry median Debt-to-EBITDA is 2.22. Redcare Pharmacy NV's value of 6.16 is 177.5% above this industry median. Based on the distribution chart, Redcare Pharmacy NV ranks #409 out of 477 companies in the Healthcare Providers & Services industry, which is in the bottom quartile relative to peers. Overall, Redcare Pharmacy NV has a GF Score™ of 69/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Redcare Pharmacy NV's Debt-to-EBITDA compare to competitors?
According to the Healthcare Providers & Services industry distribution chart, Redcare Pharmacy NV ranks #409 out of 477 companies for Debt-to-EBITDA. This places Redcare Pharmacy NV in the lower half of its industry. The industry median Debt-to-EBITDA is 2.22. Redcare Pharmacy NV's value of 6.16 is 177.5% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-EBITDA for a Healthcare Providers & Services company?
The median Debt-to-EBITDA among Healthcare Providers & Services companies is 2.22, based on 477 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Redcare Pharmacy NV's current Debt-to-EBITDA of 6.16 is 177.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-EBITDA mean?
A high Debt-to-EBITDA can signal that a stock is expensive relative to its fundamentals. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Redcare Pharmacy NV. For the Healthcare Providers & Services industry, the median Debt-to-EBITDA is 2.22 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Redcare Pharmacy NV's current Debt-to-EBITDA is 6.16. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Redcare Pharmacy NV stock overvalued right now?
Based on GuruFocus' analysis, Redcare Pharmacy NV (SHPPF) is currently considered Significantly Undervalued. The stock's GF Value™ is $175.28, compared to a current price of $64.80 — trading 63% below its estimated fair value. The current Debt-to-EBITDA is 6.16 and 177.5% above the Healthcare Providers & Services industry median of 2.22. Redcare Pharmacy NV's overall GF Score™ is 69/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-EBITDA calculated?
Debt-to-EBITDA is calculated from a company's financial statements. For Redcare Pharmacy NV (SHPPF), the current Debt-to-EBITDA is 6.16 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Redcare Pharmacy NV (SHPPF) Overvalued in 2026?
Based on GuruFocus' analysis, Redcare Pharmacy NV stock appears to be undervalued.
The current stock price of $64.80 is trading 63% below its estimated GF Value™ of $175.28.
GuruFocus considers Redcare Pharmacy NV to be Significantly Undervalued.
Key valuation signals for SHPPF:
Debt-to-EBITDA: 6.16
GF Value™: $175.28 vs. price of $64.80 (63% below fair value)
Industry Position: 177.5% above the Healthcare Providers & Services median (#409 of 477)
No single metric tells the full story. See the SHPPF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Redcare Pharmacy NV is an online pharmacy business for prescription and nonprescription (over-the-counter) pharmaceuticals, beauty and personal care products (BPC) and food supplements. Besides OTC, nutritional supplements, beauty and personal care products as well as an extensive assortment of health-related products in all markets, the company also provides prescription drugs for customers in Germany, Switzerland and the Netherlands. It operates in two segments, namely DACH segment that includes sales in Germany, Austria and Switzerland; and the International segment that includes sales across Belgium, the Netherlands, France and Italy. The DACH segment accounts for the majority of the revenue.
69GF Score
Get the complete analysis for SHPPF
Debt-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHPPF has been successfully added to your 
